Related Experiment Video
Updated: Dec 14, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
ADAMTS7 degrades Comp to fuel BMP2-dependent osteogenic differentiation and ameliorate oncogenic potential in
Chao Wang1, Yunqing Chen2, Hongfei Xiang1
1Department of Spine Surgery, The Affiliated Hospital of Qingdao University, China.
Abstract:
Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, with a high metastatic potential. Despite dramatic changes in OS treatments over the past decades, their efficiency still remains limited, with severe complications and adverse side effects. Key mechanisms underlining tumorigenesis, metastasis and chemotherapy resistance are currently lacking, in turn hindering any progress with respect to developing effective and safe therapeutic strategies against OS. Recently, ADAMTS7, a member of the disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family, was shown to be involved in osteogenic differentiation-related pathological processes. ADAMTS7 promotes vascular calcification via disturbing the balance between osteogenic bone morphogenetic protein (BMP)2 (regulating osteogenic differentiation and bone formation during development) and its natural inhibitor cartilage oligomeric matrix protein (Comp). Hence, in the present study, we aimed to investigate the role of ADAMTS7 in the pathological process of OS. We first revealed that ADAMTS7 was decreased in OS tissues. Lower expression of ADAMTS7 was correlated with poor histological differentiation and an advanced clinical stage of OS. Through loss- and gain-function analysis, we further revealed that ADAMTS7 attenuated cell proliferation, migration and invasion, at the same time as promoting the expression of osteogenic differentiation markers in two OS cell lines: MG63 and SAOS2. Moreover, Comp was responsible for the effects of ADAMTS7 on OS pathogenesis by reinforcing cell osteogenic differentiation mediated by BMP2 in vitro. In conclusion, ADAMTS7-mediated degradation of Comp may provide a potential therapeutic target for the treatment of OS.
Insights
Osteosarcoma (OS) is a common bone cancer. This study found that ADAMTS7 protein levels are lower in OS tumors, and restoring ADAMTS7 inhibits cancer cell growth and promotes bone formation, suggesting ADAMTS7 as a therapeutic target.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, characterized by high metastatic potential and limited treatment efficacy.
- Current understanding of OS tumorigenesis, metastasis, and chemotherapy resistance mechanisms is insufficient for developing effective therapies.
- ADAMTS7, a metalloproteinase, is implicated in pathological processes related to osteogenic differentiation.
Purpose of the Study:
- To investigate the role of ADAMTS7 in the pathological processes of Osteosarcoma.
- To explore the potential of ADAMTS7 as a therapeutic target for OS treatment.
Main Methods:
- Analysis of ADAMTS7 expression in OS tissues.
- Loss- and gain-of-function studies in OS cell lines (MG63 and SAOS2).
- Investigation of the interaction between ADAMTS7, Cartilage oligomeric matrix protein (Comp), and Bone morphogenetic protein 2 (BMP2).
Main Results:
- ADAMTS7 expression was decreased in OS tissues and correlated with poor differentiation and advanced clinical stage.
- Reduced ADAMTS7 expression was associated with increased OS cell proliferation, migration, and invasion.
- ADAMTS7 promoted osteogenic differentiation marker expression in OS cells.
- Comp mediated ADAMTS7's effects on OS pathogenesis by enhancing BMP2-induced osteogenic differentiation.
Conclusions:
- ADAMTS7 plays a suppressive role in Osteosarcoma progression.
- ADAMTS7-mediated degradation of Comp represents a potential therapeutic strategy for OS treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
08:04Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
